Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma
Completed · Phase 1
Conditions studied: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Drugs used in chemotherapy, such as fenretinide Lym-X-Sorb™ , work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide Lym-X-Sorb™ in treating patients with recurrent or resistant solid tumors or lymphoma.
Key facts
- Study ID
- NCT00589381
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 30
- Starts
- 2007-08-01
- Expected to finish
- 2011-03-01
- Last updated by the study team
- 2012-03-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Childrens Hospital Los Angeles — Los Angeles, California, United States
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
- Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital — Fort Lauderdale, Florida, United States
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.